Medpace Performance Gap Sparks Lawsuit
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 22 2026
0mins
Source: PRnewswire
- Performance Promise vs. Reality: Medpace's reported net book-to-bill ratio of just 1.04 for Q4 2025 starkly contrasts with the management's earlier commitment of 1.15, leading to a significant 15.9% drop in stock price on February 10, 2026, from $530.35 to $446.05, severely undermining investor confidence.
- Misleading Statements by Management: Throughout 2025, Medpace's leadership repeatedly claimed that cancellation behaviors were 'well-behaved' and projected a book-to-bill ratio above 1.15, yet the actual data revealed the highest cancellation rates in over a year, particularly in the metabolic therapeutic area, indicating a serious misjudgment by management.
- Allegations in the Lawsuit: The lawsuit alleges that Medpace's executives either knew or recklessly disregarded the potential inability of growth-driving therapeutic segments to sustain performance, asserting that reassurances about diversification and cancellation behavior were materially misleading, thus damaging shareholder transparency and trust.
- Investor Response Actions: Affected investors are advised to gather brokerage records and contact Levi & Korsinsky for a free evaluation, highlighting that even those who have sold their shares can still participate in claims, emphasizing the importance of legal action in protecting shareholder rights.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MEDP?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MEDP
Wall Street analysts forecast MEDP stock price to rise
7 Analyst Rating
1 Buy
4 Hold
2 Sell
Hold
Current: 457.090
Low
462.00
Averages
569.17
High
660.00
Current: 457.090
Low
462.00
Averages
569.17
High
660.00
About MEDP
Medpace Holdings, Inc. is a scientifically driven, global, full-service clinical contract research organization (CRO) providing phase I-IV clinical development services to the biotechnology, pharmaceutical and medical device industries. The Company partners with pharmaceutical, biotechnology, and medical device companies in the development and execution of clinical trials. The Company's drug development services focus on full-service Phase I-IV clinical development services and include development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support. The Company also provides bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. The Company's operations are principally based in North America, Europe, and Asia.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Medpace to Report Q2 2026 Financial Results
- Earnings Release Schedule: Medpace Holdings, Inc. will report its Q2 2026 financial results after market close on July 22, 2026, reflecting the company's ongoing development in the biotechnology and pharmaceutical sectors.
- Conference Call Timing: The company will host a conference call on July 23, 2026, at 9:00 a.m. ET to discuss the financial results, which is expected to attract significant attention from investors and analysts.
- Participation Requirements: Interested parties must register in advance to participate in the call, with a recommendation to join 10 minutes early to ensure smooth access and receive the dial-in number and unique PIN.
- Webcast Replay Availability: A replay of the webcast will be available approximately one hour after the call concludes on Medpace's website under the
See More
Medpace Holdings Faces Class Action Lawsuit for Securities Violations
- Class Action Initiated: Bronstein, Gewirtz & Grossman, LLC has announced a class action lawsuit against Medpace Holdings, seeking damages for investors who purchased the company's securities between April 22, 2025, and February 9, 2026, indicating strong investor response to potential violations.
- Allegations Overview: The complaint alleges that throughout the class period, defendants made materially false and misleading statements and failed to disclose critical information, which may have led to investor losses, highlighting serious deficiencies in the company's transparency.
- Investor Participation Opportunity: Affected investors are encouraged to apply to be lead plaintiffs by June 8, 2026, suggesting that the progress of this case could significantly impact the compensation outcomes for investors involved.
- Legal Fee Structure: Bronstein, Gewirtz & Grossman, LLC represents investors on a contingency fee basis, meaning they will only charge fees if the case is successful, thereby reducing financial risk for investors and encouraging broader participation in the lawsuit.
See More
Medpace Faces Class Action Lawsuit from Shareholders
- Class Action Initiated: Safirstein Law LLC has announced a class action lawsuit against Medpace Holdings, Inc., representing shareholders who purchased stock between April 22, 2025, and February 9, 2026, alleging securities fraud and other unlawful business practices.
- Earnings Report Impact: On February 9, 2026, Medpace released its fourth-quarter 2025 earnings, revealing a book-to-bill ratio of 1.04, significantly below guidance, which led to a 15.9% drop in stock price, falling $84.30 to close at $446.05, indicating market disappointment with the company's performance.
- Court Procedure Details: Shareholders wishing to serve as lead plaintiff must file with the court by June 8, 2026, highlighting the active engagement of shareholders in corporate governance and their willingness to take legal action for accountability.
- Legal Practice Focus: Safirstein Law LLC specializes in shareholder rights, emphasizing its mission to provide investor and consumer protection, suggesting that this case may attract broader legal and market scrutiny.
See More
Medpace Stock Class Action Notice Issued
- Class Action Deadline: Rosen Law Firm reminds investors who purchased Medpace Holdings, Inc. (NASDAQ: MEDP) common stock between April 22, 2025, and February 9, 2026, that they must apply to be lead plaintiff by June 8, 2026, to participate in the class action and seek compensation.
- Lawsuit Background: The lawsuit alleges that defendants made false and/or misleading statements during the class period, concealing the true state of Medpace's cancellation rates, which led investors to have overly optimistic growth expectations that could not sustain the projected 1.15 book-to-bill ratio.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and has achieved the largest securities class action settlement against a Chinese company, ranked No. 1 by ISS Securities Class Action Services in 2017, demonstrating its expertise and success in the field.
- Investor Action Advice: Investors can visit Rosen Law Firm's website or call the toll-free number for more information, emphasizing the importance of selecting qualified legal counsel to ensure proper representation in the lawsuit and avoid inexperienced intermediaries.
See More
Medpace Faces Class Action Lawsuit Allegations
- Class Action Initiation: Robbins Geller law firm announces that investors who purchased Medpace Holdings Inc. stock between April 22, 2025, and February 9, 2026, have until June 8, 2026, to seek lead plaintiff status, indicating significant investor trust issues in the company's management.
- Financial Misrepresentation Allegations: The lawsuit alleges that Medpace overstated its book-to-bill ratio for Q4 2025, reporting only 1.04 compared to the claimed 1.15, leading to a nearly 16% stock price drop post-announcement, reflecting market skepticism regarding the company's financial transparency.
- Management Accountability: The lawsuit highlights that Medpace's management failed to disclose the impact of order cancellations on the book-to-bill ratio, and their overly optimistic business outlook is viewed as misleading to investors, potentially exposing the company to greater legal and financial risks.
- Investor Rights Protection: Under the Private Securities Litigation Reform Act of 1995, any investor who purchased Medpace stock during the class period can seek lead plaintiff status, emphasizing the urgent need for the company to enhance its accountability in protecting investor rights.
See More
Medpace Faces Class Action Lawsuit Over Securities Violations
- Class Action Initiated: Bronstein, Gewirtz & Grossman, LLC has announced a class action lawsuit against Medpace Holdings, aiming to recover damages for investors who purchased securities between April 22, 2025, and February 9, 2026, reflecting significant investor dissatisfaction with the company's financial transparency.
- False Statement Allegations: The complaint alleges that Medpace repeatedly overstated its expected book-to-bill ratio for Q4 2025 at approximately 1.15 during earnings calls, despite internal information indicating otherwise, potentially leading investors to make misguided decisions based on misleading information.
- Investor Rights Protection: Affected investors have until June 5, 2026, to request to be appointed as lead plaintiff, underscoring the legal team's commitment to safeguarding investor rights while highlighting the potential impact of the class action on corporate accountability.
- Legal Fee Arrangement: Bronstein, Gewirtz & Grossman, LLC operates on a contingency fee basis, meaning they only charge fees if the lawsuit is successful, which reduces the financial burden on investors and encourages more victims to participate in the lawsuit.
See More
Medpace to Report Q2 2026 Financial Results
- Earnings Release Schedule: Medpace Holdings, Inc. will report its Q2 2026 financial results after market close on July 22, 2026, reflecting the company's ongoing development in the biotechnology and pharmaceutical sectors.
- Conference Call Timing: The company will host a conference call on July 23, 2026, at 9:00 a.m. ET to discuss the financial results, which is expected to attract significant attention from investors and analysts.
- Participation Requirements: Interested parties must register in advance to participate in the call, with a recommendation to join 10 minutes early to ensure smooth access and receive the dial-in number and unique PIN.
- Webcast Replay Availability: A replay of the webcast will be available approximately one hour after the call concludes on Medpace's website under the
See More
Medpace Holdings Faces Class Action Lawsuit for Securities Violations
- Class Action Initiated: Bronstein, Gewirtz & Grossman, LLC has announced a class action lawsuit against Medpace Holdings, seeking damages for investors who purchased the company's securities between April 22, 2025, and February 9, 2026, indicating strong investor response to potential violations.
- Allegations Overview: The complaint alleges that throughout the class period, defendants made materially false and misleading statements and failed to disclose critical information, which may have led to investor losses, highlighting serious deficiencies in the company's transparency.
- Investor Participation Opportunity: Affected investors are encouraged to apply to be lead plaintiffs by June 8, 2026, suggesting that the progress of this case could significantly impact the compensation outcomes for investors involved.
- Legal Fee Structure: Bronstein, Gewirtz & Grossman, LLC represents investors on a contingency fee basis, meaning they will only charge fees if the case is successful, thereby reducing financial risk for investors and encouraging broader participation in the lawsuit.
See More
Medpace Faces Class Action Lawsuit from Shareholders
- Class Action Initiated: Safirstein Law LLC has announced a class action lawsuit against Medpace Holdings, Inc., representing shareholders who purchased stock between April 22, 2025, and February 9, 2026, alleging securities fraud and other unlawful business practices.
- Earnings Report Impact: On February 9, 2026, Medpace released its fourth-quarter 2025 earnings, revealing a book-to-bill ratio of 1.04, significantly below guidance, which led to a 15.9% drop in stock price, falling $84.30 to close at $446.05, indicating market disappointment with the company's performance.
- Court Procedure Details: Shareholders wishing to serve as lead plaintiff must file with the court by June 8, 2026, highlighting the active engagement of shareholders in corporate governance and their willingness to take legal action for accountability.
- Legal Practice Focus: Safirstein Law LLC specializes in shareholder rights, emphasizing its mission to provide investor and consumer protection, suggesting that this case may attract broader legal and market scrutiny.
See More
Medpace Stock Class Action Notice Issued
- Class Action Deadline: Rosen Law Firm reminds investors who purchased Medpace Holdings, Inc. (NASDAQ: MEDP) common stock between April 22, 2025, and February 9, 2026, that they must apply to be lead plaintiff by June 8, 2026, to participate in the class action and seek compensation.
- Lawsuit Background: The lawsuit alleges that defendants made false and/or misleading statements during the class period, concealing the true state of Medpace's cancellation rates, which led investors to have overly optimistic growth expectations that could not sustain the projected 1.15 book-to-bill ratio.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and has achieved the largest securities class action settlement against a Chinese company, ranked No. 1 by ISS Securities Class Action Services in 2017, demonstrating its expertise and success in the field.
- Investor Action Advice: Investors can visit Rosen Law Firm's website or call the toll-free number for more information, emphasizing the importance of selecting qualified legal counsel to ensure proper representation in the lawsuit and avoid inexperienced intermediaries.
See More
Medpace Faces Class Action Lawsuit Allegations
- Class Action Initiation: Robbins Geller law firm announces that investors who purchased Medpace Holdings Inc. stock between April 22, 2025, and February 9, 2026, have until June 8, 2026, to seek lead plaintiff status, indicating significant investor trust issues in the company's management.
- Financial Misrepresentation Allegations: The lawsuit alleges that Medpace overstated its book-to-bill ratio for Q4 2025, reporting only 1.04 compared to the claimed 1.15, leading to a nearly 16% stock price drop post-announcement, reflecting market skepticism regarding the company's financial transparency.
- Management Accountability: The lawsuit highlights that Medpace's management failed to disclose the impact of order cancellations on the book-to-bill ratio, and their overly optimistic business outlook is viewed as misleading to investors, potentially exposing the company to greater legal and financial risks.
- Investor Rights Protection: Under the Private Securities Litigation Reform Act of 1995, any investor who purchased Medpace stock during the class period can seek lead plaintiff status, emphasizing the urgent need for the company to enhance its accountability in protecting investor rights.
See More
Medpace Faces Class Action Lawsuit Over Securities Violations
- Class Action Initiated: Bronstein, Gewirtz & Grossman, LLC has announced a class action lawsuit against Medpace Holdings, aiming to recover damages for investors who purchased securities between April 22, 2025, and February 9, 2026, reflecting significant investor dissatisfaction with the company's financial transparency.
- False Statement Allegations: The complaint alleges that Medpace repeatedly overstated its expected book-to-bill ratio for Q4 2025 at approximately 1.15 during earnings calls, despite internal information indicating otherwise, potentially leading investors to make misguided decisions based on misleading information.
- Investor Rights Protection: Affected investors have until June 5, 2026, to request to be appointed as lead plaintiff, underscoring the legal team's commitment to safeguarding investor rights while highlighting the potential impact of the class action on corporate accountability.
- Legal Fee Arrangement: Bronstein, Gewirtz & Grossman, LLC operates on a contingency fee basis, meaning they only charge fees if the lawsuit is successful, which reduces the financial burden on investors and encourages more victims to participate in the lawsuit.
See More
